- Home
- BRW vs AGEN Comparison
BRW vs AGEN Comparison
Compare BRW & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRW
- AGEN
- Stock Information
- Founded
- BRW 1987
- AGEN 1994
- Country
- BRW United States
- AGEN United States
- Employees
- BRW N/A
- AGEN N/A
- Industry
- BRW Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BRW Finance
- AGEN Health Care
- Exchange
- BRW Nasdaq
- AGEN Nasdaq
- Market Cap
- BRW 333.0M
- AGEN 87.7M
- IPO Year
- BRW N/A
- AGEN 2000
- Fundamental
- Price
- BRW $8.12
- AGEN $7.27
- Analyst Decision
- BRW
- AGEN Buy
- Analyst Count
- BRW 0
- AGEN 4
- Target Price
- BRW N/A
- AGEN $13.00
- AVG Volume (30 Days)
- BRW 222.1K
- AGEN 1.4M
- Earning Date
- BRW 01-01-0001
- AGEN 08-07-2025
- Dividend Yield
- BRW 15.59%
- AGEN N/A
- EPS Growth
- BRW N/A
- AGEN N/A
- EPS
- BRW N/A
- AGEN N/A
- Revenue
- BRW N/A
- AGEN $99,524,000.00
- Revenue This Year
- BRW N/A
- AGEN $12.69
- Revenue Next Year
- BRW N/A
- AGEN N/A
- P/E Ratio
- BRW N/A
- AGEN N/A
- Revenue Growth
- BRW N/A
- AGEN N/A
- 52 Week Low
- BRW $7.15
- AGEN $1.38
- 52 Week High
- BRW $8.30
- AGEN $18.74
- Technical
- Relative Strength Index (RSI)
- BRW 65.91
- AGEN 68.42
- Support Level
- BRW $8.06
- AGEN $4.78
- Resistance Level
- BRW $8.18
- AGEN $6.20
- Average True Range (ATR)
- BRW 0.08
- AGEN 0.62
- MACD
- BRW 0.00
- AGEN 0.10
- Stochastic Oscillator
- BRW 82.86
- AGEN 98.90
About BRW Saba Capital Income & Opportunities Fund SBI
Saba Capital Income & Opportunities Fund is a diversified, closed-end management investment company. It seeks to provide investors with a high level of current income, with a secondary goal of capital appreciation. It invests globally in debt and equity securities of public and private companies, which includes, investing in closed-end funds, public and private debt instruments, and other securities.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).